F-18FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer

Stanford University, Palo Alto, California, United States
Clinical Nuclear Medicine (Impact Factor: 2.86). 02/2007; 32(1):13-5. DOI: 10.1097/01.rlu.0000249591.51354.3e
Source: PubMed

ABSTRACT An adrenal metastasis was identified on an F-18 FDG PET/CT scan in a patient with anaplastic thyroid cancer. There are very few reports of thyroid cancer, even anaplastic thyroid cancer, metastasizing to the adrenal.

  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the surgical outcomes of endoscopic dacryocystorhinostomy with canalicular marsupialization (EDCR CM) in common canalicular obstruction. Retrospective review of medical records. Thirty-six patients (38 eyes) who had undergone EDCR CM for chronic epiphora caused by common canalicular obstruction. Surgical outcomes were evaluated postoperatively by improvement of subjective symptoms and patency of the neo-ostium of DCR on nasal endoscopy. Subjective symptoms improved in 81.6% (31/38) after primary EDCR CM and 94.7% (36/38) after revision surgery. In cases of silicone stent intubation, the surgical results were relatively superior compared with patients without silicon stent insertion (83.3% and 75.0%, respectively; p = 0.624). On postoperative nasal examination after primary surgery, the patency of dacryocystorhinostomy site was lower in patients with silicone stent insertion than those without (86.70% and 100%, respectively; p = 0.560), and the patency rate of the canalicular neo-ostium was higher in patients with silicone stent insertion than those without (90.0% and 75.0%, respectively; p = 0.279). There were no serious intraoperative complications except mild punctual erosion (4 patients, 10.5%). EDCR CM showed favourable surgical outcomes and few surgical complications. This surgical treatment could be the first-line treatment for patients with distal common canalicular obstruction.
    Canadian Journal of Ophthalmology 08/2013; 48(4):335-9. DOI:10.1016/j.jcjo.2013.02.012 · 1.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Adrenal metastasis is common in oncology but patients with this diagnosis are usually asymptomatic. The diagnosis can be challenging and delayed. Incidence, presenting symptoms and diagnostic modalities are reviewed. Various treatment options are also discussed, including open and laparoscopic surgery, local ablation (radiofrequency ablation, cryoablation, microwave thermal ablation, and chemical ablation) as well as radiation therapy. These treatment modalities were compared and contrasted in regards to their invasiveness, risks, side effects, outcomes, and patients’ tolerance. Radiotherapy including stereotactic body radiation therapy (SBRT) is the only non-invasive approach, which is important as majority of the patients with adrenal metastases also receive systemic therapy, e.g., chemotherapy. The initial goal of conventional radiotherapy for metastatic adrenal lesion is for palliation which has been shown to be effective. With the advent of technological advances in radiation oncology, e.g., image-guidance during radiation delivery, patient immobilization and patient re-positioning, tumor motion management, sophisticated treatment planning allowing rapid dose fall-off, accurate QA, etc., the clinical implementation of SBRT has been very successful. SBRT is defined as a “treatment method to deliver high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body”. Adrenal metastasis, an example of oligometastases even from radioresistant primary, could be successfully treated with SBRT without significant toxicity as evidenced by various recently reported clinical trials. An additional advantage could be adrenal function preservation when compared to surgical intervention. The optimal total dose and fractionation scheme are yet to be determined. SBRT is an emerging non-invasive, safe, and effective treatment modality, and further research is warranted to define its role in the management of adrenal metastasis.
    03/2012; 1(1). DOI:10.1007/s13566-012-0012-4
  • Source
    Nuclear Medicine and Molecular Imaging 09/2014; DOI:10.1007/s13139-014-0293-1